Put Options

18 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Jan 18, 2024

BUY
$1.32 - $4.83 $2,640 - $9,660
2,000 New
2,000 $1,000
Q4 2022

Feb 07, 2023

SELL
$5.77 - $8.49 $69,240 - $101,880
-12,000 Reduced 77.92%
3,400 $3,000
Q3 2022

Oct 25, 2022

BUY
$3.75 - $7.39 $12,750 - $25,126
3,400 Added 28.33%
15,400 $11,000
Q2 2022

Aug 04, 2022

BUY
$2.94 - $5.23 $26,460 - $47,070
9,000 Added 300.0%
12,000 $22,000
Q1 2022

Apr 14, 2022

BUY
$4.07 - $10.6 $10,175 - $26,500
2,500 Added 500.0%
3,000 $7,000
Q4 2021

Jan 18, 2022

SELL
$8.96 - $16.31 $11,648 - $21,203
-1,300 Reduced 72.22%
500 $2,000
Q3 2021

Oct 26, 2021

BUY
$11.24 - $21.0 $20,232 - $37,800
1,800 New
1,800 $3,000
Q2 2021

Jul 19, 2021

SELL
$18.04 - $22.09 $3,608 - $4,418
-200 Closed
0 $0
Q1 2021

Apr 26, 2021

SELL
$16.59 - $33.89 $46,452 - $94,892
-2,800 Reduced 93.33%
200 $0
Q1 2020

May 07, 2020

BUY
$26.16 - $63.5 $23,544 - $57,150
900 Added 42.86%
3,000 $77,000
Q3 2019

Oct 28, 2019

SELL
$59.47 - $93.1 $446,025 - $698,250
-7,500 Reduced 78.13%
2,100 $175,000
Q2 2019

Aug 09, 2019

BUY
$75.84 - $105.21 $568,800 - $789,075
7,500 Added 357.14%
9,600 $144,000
Q1 2019

May 10, 2019

SELL
$64.44 - $104.11 $386,640 - $624,660
-6,000 Reduced 74.07%
2,100 $82,000
Q3 2018

Nov 07, 2018

SELL
$88.86 - $117.49 $346,554 - $458,211
-3,900 Reduced 32.5%
8,100 $118,000
Q2 2018

Aug 10, 2018

SELL
$99.64 - $127.59 $597,840 - $765,540
-6,000 Reduced 33.33%
12,000 $259,000
Q1 2018

May 11, 2018

SELL
$105.8 - $150.94 $719,440 - $1.03 Million
-6,800 Reduced 27.42%
18,000 $338,000
Q4 2017

Jan 17, 2018

SELL
$81.25 - $130.7 $910,000 - $1.46 Million
-11,200 Reduced 31.11%
24,800 $167,000
Q3 2017

Oct 17, 2017

BUY
$57.74 - $91.42 $2.08 Million - $3.29 Million
36,000
36,000 $158,000

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $708M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.